依达拉奉对高血压性脑出血患者血浆神经元特异性烯醇化酶及预后的影响

The Effect of Edaravone on on Plasma NSE Levels and the Prognosis after Hypertensive Intracerebral Hemorrhage

目的观察高血压性脑出血患者使用依达拉奉后血浆神经元特异性烯醇化酶（NSE）的变化及其对预后的影响。方法将我院收治的85例高血压性脑出血患者随机分为对照组和依达拉奉治疗组,动态观察患者的血浆NSE水平、血肿体积、神经功能缺损程度和总的生活能力评分。结果两组患者的血浆NSE水平在各个时间点上无明显差异,依达拉奉治疗组与对照组的临床神经功能缺损程度及生活能力评分在病程第14天时无显著性差异,在第30、90d时治疗组的神经功能恢复优于对照组。结论脑出血急性期静脉应用依达拉奉有可能改善患者的预后。血浆NSE不宜做为临床评价脑出血药物疗效的指标。

Objective： To investigate the effects of the Edarsvone on the plasma neuron-specific enolase （NSE） levels and the prognosis in the patients with acute hypertensive intracerebral hemorrhage. Methods 85 patients with acute hypertensive intraeerebral cerebral hemorrhage were divided randomly into and edarsvone with plasma NSE levels, hematoma volume,clinical neurological states and general living ability observed dynamically. Results There was no significant difference of plasma NSE levels between the treatment group and the at each point of time, also of clinical neurological state and general living ability between them on the 14th day. The prognosis of neurological state in the treatment group were better than that in the on day 30th,90th after the symptom onset. Conclusion Edarsvone may be useful to improve the prognosis after hypertensive intracerebral hemorrhage. Plasma NSE level is not helpful to evaluate the theraputic efficacy of drugs in the patients with acute hypertensive intracerebral hemorrhage.